AOD-9604 and Levothyroxine Interaction: Safety, Timing, and Monitoring

Why This Combination Comes Up

AOD-9604 (the modified fragment spanning amino acids 176 to 191 of human growth hormone) is used off-label for fat loss in patients who may also carry a hypothyroidism diagnosis. Hypothyroidism itself affects roughly 4.6% of the U.S. Population aged 12 and older, per NHANES data published by the National Institute of Diabetes and Digestive and Kidney Diseases [3]. The overlap between patients seeking adipose-modulation peptides and those on thyroid replacement is therefore common enough to warrant a structured review.

The Clinical Scenario

A patient stable on levothyroxine 75 to 150 mcg daily begins a compounded AOD-9604 protocol (typically 250 to 300 mcg subcutaneously each morning). Both agents perform best on an empty stomach. That shared requirement creates the core timing problem.

Why Prescribers Should Care

Levothyroxine has one of the narrowest therapeutic indices of any oral medication. The American Thyroid Association (ATA) guidelines state that even small changes in absorption can shift TSH by 20 to 30% within 4 to 6 weeks [2]. Any new co-administered agent, even one without a direct molecular interaction, deserves scrutiny if it could alter levothyroxine uptake.

Pharmacokinetic Interaction Profile

Neither AOD-9604 nor levothyroxine participates meaningfully in cytochrome P450 metabolism, and neither is a substrate or inhibitor of P-glycoprotein (P-gp). The interaction risk here is not enzymatic. It is physical and absorptive.

Levothyroxine Absorption Basics

Levothyroxine (T4) is absorbed primarily in the jejunum and upper ileum. Oral bioavailability ranges from 40 to 80% in the fasting state and drops significantly when gastric pH rises or when other substances compete for mucosal contact. A 2017 study in Thyroid demonstrated that co-ingestion with coffee alone reduced T4 absorption by up to 36% [4]. Calcium, iron, and proton pump inhibitors are well-documented offenders listed on the FDA-approved levothyroxine label [5].

AOD-9604 Absorption and Clearance

AOD-9604 is a 16-amino-acid peptide fragment. When administered subcutaneously, it bypasses the GI tract entirely, which eliminates the absorption-competition concern for that route. Oral AOD-9604 capsules, however, pass through the stomach and small intestine. Peptide fragments can transiently alter gastric motility and local pH buffering. No published pharmacokinetic study has measured whether oral AOD-9604 specifically impairs levothyroxine absorption, but the general principle of "anything in the stomach during the levothyroxine absorption window is a risk" applies.

CYP and Transporter Summary

| Pathway | Levothyroxine | AOD-9604 | |---|---|---| | CYP3A4 | Not a substrate | Not a substrate | | CYP2D6 | Not a substrate | Not a substrate | | P-glycoprotein | Not a significant substrate | No data (peptide, likely not) | | UGT glucuronidation | Minor T4 conjugation in liver | Not applicable | | OATP transporters | OATP1C1 for CNS uptake of T4 | No known interaction |

The bottom line: no enzyme-mediated or transporter-mediated interaction is expected.

Pharmacodynamic Considerations

The pharmacodynamic question is whether AOD-9604 alters thyroid axis signaling itself, independent of absorption.

Growth Hormone Fragment and the HPT Axis

Full-length human growth hormone (hGH) is known to accelerate peripheral conversion of T4 to T3 via increased activity of type 1 deiodinase, and it can suppress TSH through enhanced somatostatin tone. A 2012 analysis in the Journal of Clinical Endocrinology & Metabolism found that GH replacement therapy in GH-deficient adults unmasked central hypothyroidism in 36 to 47% of patients [6].

AOD-9604, however, is a truncated C-terminal fragment that retains the lipolytic activity of hGH but lacks the somatotropic and IGF-1-stimulating domains. Preclinical data from the Obesity Research group at Monash University showed that AOD-9604 did not raise IGF-1 levels in obese Zucker rats at lipolytic doses [7]. Without IGF-1 elevation, the deiodinase-accelerating effect of full-length GH is not expected.

What This Means Clinically

The risk of AOD-9604 altering T4-to-T3 conversion or suppressing TSH through a GH-like mechanism appears low based on available preclinical evidence. No human trial has directly measured thyroid function changes during AOD-9604 use. That absence of data is not the same as proof of safety. It means monitoring is required.

Dose Separation Protocol

The single most effective risk-mitigation step is proper timing. The goal is to protect levothyroxine's fasting absorption window while also giving AOD-9604 an empty-stomach environment for optimal peptide uptake.

Recommended Schedule

Option A (subcutaneous AOD-9604):

1. Wake. Take levothyroxine with 8 oz plain water.
2. Wait 30 to 60 minutes (per ATA 2014 guidelines [2]).
3. Administer AOD-9604 subcutaneously at any point after the levothyroxine absorption window closes.
4. Wait 15 to 20 minutes before eating.

Because subcutaneous AOD-9604 does not enter the GI tract, the separation here is primarily to avoid any indirect gastric motility changes from the injection.

Oral AOD-9604 Timing

Option B (oral AOD-9604 capsule):

1. Wake. Take levothyroxine with plain water.
2. Wait a full 60 minutes (not 30) before taking oral AOD-9604.
3. Wait another 20 to 30 minutes before eating.

The extended 60-minute buffer accounts for the unknown but plausible risk of peptide-fragment interference with jejunal T4 absorption.

Evening Dosing Alternative

Some patients prefer bedtime levothyroxine. A randomized crossover trial published in the Archives of Internal Medicine (N=90) found that bedtime dosing produced lower TSH values (mean 1.25 vs. 2.19 mIU/L) compared to morning dosing, likely due to a longer fasting interval [8]. For patients on oral AOD-9604 in the morning, moving levothyroxine to bedtime (at least 3 hours after the last meal) eliminates the timing conflict entirely.

Monitoring Plan After Adding AOD-9604

Thyroid function should be rechecked after any change to a co-administered substance, even if no direct interaction is expected.

Lab Schedule

| Timepoint | Test | Target | |---|---|---| | Baseline (before starting AOD-9604) | TSH, free T4, free T3 | Document stable values | | 6 weeks after starting AOD-9604 | TSH, free T4 | Detect early absorption shifts | | 12 weeks | TSH, free T4, free T3 | Confirm stability | | Every 6 months thereafter | TSH | Routine per ATA guidelines [2] |

Red Flags That Warrant Earlier Testing

A return of hypothyroid symptoms (fatigue, cold intolerance, constipation, unexplained weight gain) within the first 4 weeks of adding AOD-9604 should prompt an immediate TSH and free T4 draw. A TSH rise of more than 1.0 mIU/L from baseline suggests absorption interference, and the dose-separation protocol should be reviewed before adjusting the levothyroxine dose.

When to Adjust Levothyroxine

Do not reflexively increase the levothyroxine dose if TSH rises after adding AOD-9604. First, confirm the patient is following the timing protocol. Second, consider switching from oral AOD-9604 to subcutaneous injection, which removes the absorption variable. Only after these steps should a levothyroxine dose adjustment (typically 12.5 to 25 mcg) be considered, followed by repeat TSH at 6 weeks.

AOD-9604 Regulatory and Safety Context

AOD-9604 is not an FDA-approved drug. It is available through compounding pharmacies under section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA's Bulk Drug Substances Advisory Committee has reviewed AOD-9604 for inclusion on the 503B bulks list, and discussions remain ongoing [9].

What the Phase 2 Trial Showed

The largest human dataset comes from a phase 2b trial (Metabolic Pharmaceuticals, 2006) of oral AOD-9604 in 536 obese adults. Over 24 weeks, the peptide did not meet its primary endpoint for weight loss versus placebo. Thyroid function was not a reported secondary endpoint, which limits direct extrapolation. No serious adverse events attributable to thyroid disruption were reported in the published safety data [7].

Compounding Quality Matters

Because AOD-9604 is compounded, potency and purity vary by pharmacy. Excipients in oral formulations (fillers, pH buffers, coatings) could independently affect levothyroxine absorption. Patients should use a 503A-registered pharmacy that provides certificates of analysis, and they should report any formulation changes to their prescriber.

Special Populations

Patients on Combination T4/T3 Therapy

Patients taking both levothyroxine and liothyronine (T3) face a doubled timing burden. Liothyronine is typically dosed twice daily and also requires fasting conditions for reliable absorption. Adding AOD-9604 to this regimen demands strict scheduling. A written dosing timetable, reviewed with the patient at each visit, is the most practical safeguard.

Patients With Thyroid Cancer on Suppressive Doses

Post-thyroidectomy patients on TSH-suppressive levothyroxine doses (goal TSH <0.1 mIU/L) have zero margin for absorption loss. Any rise in TSH from peptide co-administration could compromise oncologic suppression. For these patients, subcutaneous AOD-9604 is strongly preferred over oral, and TSH should be checked at 4 weeks rather than 6.

Elderly Patients and Cardiac Risk

Patients over 65 with coronary artery disease are started on low-dose levothyroxine (25 to 50 mcg) and titrated slowly because excess T4 can precipitate angina or arrhythmia. Fluctuating absorption from inconsistent AOD-9604 timing could push free T4 levels in either direction. The Endocrine Society clinical practice guideline recommends more frequent TSH monitoring in elderly patients during any medication change [10].

Patient Counseling Points

Practical instructions reduce errors more than pharmacology lectures. These five directives should appear in the patient's after-visit summary:

1. Take levothyroxine first thing in the morning with plain water only. No coffee, no supplements, no peptides for at least 60 minutes.
2. If using subcutaneous AOD-9604, inject it after the 60-minute levothyroxine window.
3. If using oral AOD-9604, wait a full 60 minutes after levothyroxine, then wait another 20 minutes before eating.
4. Report any new fatigue, weight gain, hair thinning, or constipation within the first 8 weeks.
5. Bring your AOD-9604 certificate of analysis to every endocrinology visit so your prescriber can check for excipient changes.

"Patients frequently underestimate how sensitive levothyroxine is to co-administration timing. Even a 15-minute overlap with another oral agent can shift TSH measurably," per ATA recommendations on medication timing [2].

Summary of Interaction Severity

| Domain | Risk Level | Basis | |---|---|---| | CYP450 interaction | None expected | Neither drug is a CYP substrate | | P-gp interaction | None expected | Neither drug is a significant P-gp substrate | | Absorption interference (oral AOD-9604) | Low to moderate | General peptide-in-stomach concern; no direct study | | Absorption interference (SubQ AOD-9604) | Negligible | Bypasses GI tract | | Pharmacodynamic (thyroid axis) | Low | AOD-9604 does not raise IGF-1 at standard doses [7] | | Overall clinical severity | Low with proper timing | Monitoring required for first 12 weeks |

Baseline TSH and free T4 before starting AOD-9604, repeat at 6 weeks, and a written dose-separation schedule handed to the patient at the prescribing visit: that three-step protocol covers the clinically actionable risk.